Category: Accesswire

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, CEO Dr Raza Bokhari joined Steve Darling from Proactive https://youtu.be/8EErx6aQEXs to announce that the company was honored with the opportunity to ring the Nasdaq Opening Bell at the Nasdaq MarketSite in New York’s Times Square, marking the one-year anniversary of Medicus’ listing on the Nasdaq exchange.

Dr. Bokhari said the milestone reflects the company’s progress since going public and highlights its continued focus on disciplined execution across a streamlined and strategically selected clinical portfolio. Since its Nasdaq debut, Medicus has concentrated on advancing key therapeutic assets through Phase 2 proof-of-concept studies while actively pursuing licensing opportunities and strategic partnerships with established pharmaceutical companies that are well positioned to manage late-stage development and global commercialization.

Medicus’ current development pipeline is anchored by two lead programs. SkinJect is a localized, immunogenic precision therapy being developed for the treatment of basal cell carcinoma, the most common form of skin cancer. The company estimates SkinJect addresses a market opportunity of approximately $2 billion.

The pipeline also includes Teverelix, a next-generation gonadotropin-releasing hormone (GnRH) antagonist designed for patients with advanced prostate cancer who are at high cardiovascular risk and susceptible to acute urinary retention relapse. Medicus estimates the combined market opportunity for its pipeline assets at approximately $6 billion. The company announced today that the royalty rate payable on worldwide net sales of Teverelix has been reduced from ~4% to 2%, with the royalty term clarified on a country-by-country basis in line with standard industry practice. The company says this makes Teverelix more attractiveness for future partnering.

The video of the proactive interview is available by clicking on this link https://youtu.be/8EErx6aQEXs

For further information contact:

Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com

Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicuspharma.com

About Medicus Pharma Ltd.
Medicus Pharma Ltd. (Nasdaq:MDCX) is a precision-guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries across three continents.

SkinJect Inc., a wholly owned subsidiary of Medicus Pharma Ltd., is a development-stage life sciences company focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumor cells. The Company completed a Phase 1 study (SKNJCT-001) in March of 2021, which met its primary objective of demonstrating safety and tolerability; the study also describes the efficacy of the investigational product doxorubicin-containing microneedle arrays (D-MNA), with six participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.

In August 2025, the Company announced its entry into a non-binding memorandum of understanding (MoU) with Helix Nanotechnologies, Inc. (HelixNano), a Boston-based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next-generation gonadotrophin-releasing hormone (GnRH) antagonist, as a first-in-market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes .

In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in 50 patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met, with the probability dropping to 82.5% by Day 42.

In January 2023, the U.S. Food and Drug Administration (FDA) reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev’s proposed Phase 3 trial design for Teverelix. This milestone supports the Company’s clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.

In December 2023, the FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.

In November 2024, the FDA approved the Phase 2b study design in AURr covering 390 patients.

In October 2025, the Company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SkinJect for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.

Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the FDA to allow patients with multiple, recurrent, or inoperable basal cell carcinomas (BCCs) to access SkinJect under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SkinJect in this rare disease population.

In November 2025, the Company received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating D-MNA to non-invasively treat BCC of the skin. The approvals were issued by the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA) and the Wales Research Ethics Committee (WREC). The MHRA approval followed a comprehensive scientific review of the Investigational Medicinal Product Dossier (IMPD) and protocol. The WREC issued a favorable ethical opinion, and the HRA granted study-wide governance approval, confirming compliance with UK Good Clinical Practice and National Health Service capacity and capability standards.

In December 2025, the Company announced that it has successfully completed enrolment of 90 patients in the United States for Phase 2 clinical study (SKNJCT-003) evaluating D-MNA to non-invasively treat BCC of the skin. The Company expects to release topline results for SKNJCT-003 in the first quarter of 2026 and secure an end-of-Phase 2 meeting with the FDA in the first half of 2026.

In December 2025, Medicus announced a non-binding letter of intent with Reliant AI Inc., a decision-intelligence company specializing in generative AI for the life sciences industry, to collaborate on the development of an AI-driven clinical data analytics platform. Subject to execution of definitive agreements, the platform is expected to support capital-efficient clinical development through data-driven dynamic clinical-site selection, patient stratification and enrollment forecasting. The initial phase of the collaboration is expected to support an upcoming Teverelix clinical study planned for 2026, with potential expansion into later-stage development programs in collaboration with a strategic partner.

Cautionary Notice on Forward-Looking Statements
Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Company’s leadership and prospects, the collaboration with GSA including the potential benefits thereof for GSA, those suffering with Gorlin Syndrome and Medicus (including as it relates to the development of SkinJect™), ability to be approved for the Expanded Access IND Program to enable those suffering with Gorlin Syndrome to access SkinJect™ under physician-supervised treatment protocols, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr, high CV risk prostate cancer, women’s health indications like endometriosis, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, including with respect to the Company’s submission for approval in the FDA Commissioner’s National Priority Voucher program, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the Company’s expectation to release topline results for SKNJCT-003 in the first quarter of 2026 and to secure an EOP2 meeting with the FDA in the first half of 2026, entry into definitive documents with Reliant and the expected terms thereof, engaging in proposed Medicus-sponsored studies currently contemplated in the Reliant non-binding letter of intent and the expected benefits thereof, the expansion of SKNJCT-003 into the United Kingdom and the potential benefits therefrom, the advancement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2024 (the “Annual Report”), and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

SOURCE: Medicus Pharma Ltd

View the original press release on ACCESS Newswire

Expanding Gold and Critical Elements in the Mineral-Rich Province of New Brunswick, Canada

MIRAMICHI, NB / ACCESS Newswire / January 23, 2026 / SLAM Exploration Ltd. (TSXV:SXL) (“SLAM” or the “Company“) is pleased to report that it has commenced a VTEM™-Plus airborne electromagnetic survey over the Goodwin copper-nickel-cobalt project in the mineral rich province of New Brunswick. The Company expects the VTEM survey to help identify potential ovoid-type copper-nickel-cobalt deposits associated with deep-seated magmatic chambers, as well as potential extensions of the Farqharson, Granges, Logan and Bruce copper-nickel-cobalt zones. The Company has selected Geotech Ltd, a global leader in airborne geophysical technology, to complete an 852 kilometer survey at an estimated cost of $275,000.

THE VTEM Survey is a follow-up to Slam’s 25 hole diamond drilling campaign completed in 2024 and 2025. The proposed survey outline is shown in Figure 1:

Figure 1: Proposed Goodwin VTEM Survey Area

Final assays have been received from the 2025 drilling campaign, following the 2024 campaign results previously reported. Highlights from the 2024 program included 15 holes, with results including a 64.90 meter core interval grading 2.19% Cu-Eq (copper-nickel-cobalt), including 3.84% copper equivalent (“Cu-Eq”) over 31.20 meters in hole GW24-02, as reported in a news release dated August 7, 2024. Significant gold values were also reported, including up to 3.31 grams per tonne over 0.5m in hole GW24-01.

The 2025 results are summarized in the following table:

Hole ID	From m	To m	Length m	Copper %	Nickel %	Cobalt %	Recovered* Cu-Eq%
GW2516	10.63	11.15	0.52	1.90	1.36	0.12	4.30
GW2516	72.00	73.00	1.00	1.44	0.30	0.02	2.04
GW2516	77.50	80.68	3.18	0.39	0.81	0.05	1.70
GW2516	69.50	80.68	11.18	0.45	0.36	0.03	1.16
GW2516	124.50	129.00	4.50	0.97	0.96	0.07	2.65
GW2517	98.00	146.00	48.00	0.44	0.37	0.04	2.52
GW2517	160.40	165.50	5.10	0.51	0.17	0.02	1.15
GW2518	46.75	62.50	15.75	0.56	0.10	0.01	1.01
GW2518	103.90	117.40	13.50	0.50	0.11	0.01	0.73
GW2519	76.10	150.90	74.80	0.37	0.38	0.05	0.67
GW2520	85.70	160.60	74.90	0.35	0.24	0.03	0.63
GW2521	55.50	101.50	46.00	0.30	0.23	0.03	1.08
GW2522	199.90	200.30	0.40	0.35	0.07	0.01	1.14
GW2523	62.00	67.00	5.00	0.48	0.51	0.05	1.00
GW2524	173.40	267.50	94.10	0.21	0.23	0.02	0.61
GW2525	184.25	186.35	2.10	0.18	0.25	0.03	0.56

*The recovered Cu-Eq grades are based upon data from Daily Metal Price and are based upon an assumed recovery rate of 90%.

The Company completed 10 holes for a total of 2944 meters of diamond drilling in 2025. The coordinates and other collar data are summarized in the following table.

Hole_ID	E_UTM	N_UTM	Elev	Az	Dip	Core Size	Length_m
GW2415	697230	5239320	407	60	-50	NQ	341
GW2516	697208	5238922	447	115	-70	NQ	308
GW2517	698053	5238576	490	45	-70	NQ	452
GW2518	698036	5238616	483	42	-70	NQ	170
GW2519	698094	5238571	501	44	-65	NQ	191
GW2520	698125	5238543	495	44	-65	NQ	188
GW2521	698171	5238542	495	44	-65	NQ	152
GW2522	698011	5238503	517	43	-65	NQ	455
GW2523	698333	5238556	503	220	-50	NQ	104
GW2524	698364	5238591	507	220	-50	NQ	314
GW2525	698396	5238563	508	220	-50	NQ	269

QA-QC Procedures: Core was collected from the drill in trays and delivered to a secure logging facility in Bathurst, New Brunswick. After logging, samples were sawn using a diamond blade. Sawn half-core samples were numbered, collected in bags, tagged and delivered to Activation Laboratories Ltd. (“Actlabs”) in Fredericton. Actlabs completed multi-element analysis using assay method UT7. Samples returning over-limit results (greater than 1%) for the UT7 are re-analyzed using method 8-AR. Blanks and standards are included in each sample series.

Options Granted:
SLAM’s board of directors has approved the grant of incentive stock options (“Options”) to directors, officers, employees and consultants to acquire a total of 3,100,000 common shares in the capital of the Company at an exercise price of $0.08. The Options were granted pursuant to the Company’s 10% rolling stock option plan (the “Plan”) and are subject to the terms of the Plan and the requirements of the TSX Venture Exchange. The Options are exercisable for a three-year term and expire on January 23, 2029.

Jake Lee Project Update
Assays are pending on 700 soil samples collected from the vicinity of the No. 1 gold vein on SLAM’s wholly-owned Jake Lee claims. Three channel samples from the No. 1 vein assayed 31.3 g/t gold, 12.3 g/t gold and 40.5 g/t gold along with 63.30 g/t silver, 23.2 g/t silver and 25.1 g/t silver respectively as reported by news release January 14, 2026.

The Jake Lee claims are located 25 kilometers southeast of the Clarence Stream gold deposit where Galway Metals Inc. Clarence Stream is host to a 12.4M tonne indicated resource of 922,000 ounces at a grade of 2.31 g/t gold plus an inferred resource of 16.1m tonnes with 1,334,000 ounces at a grade of 2.60 g/t gold. (Reference: “Updated Mineral Resource Statement, Clarence Stream Deposits, New Brunswick, Canada, by SLR Consulting (Canada) Ltd., March 31, 2022”).

Historic Menneval Results
SLAM previously reported gold bearing core intervals from the Maisie vein, including 162.5 g/t gold over 0.2 m and 56.90 g/t gold over 0.5 m, in news releases dated December 13, 2021 and November 22, 2022. The Company also reported a core interval grading 3,955 g/t (127oz) gold over 0.1m from the No. 18 vein. The Menneval soil geochemical survey shows a number of gold anomalies over an area measuring approximately 3,000 meters by 2,500 meters.

About SLAM Exploration Ltd: SLAM Exploration Ltd. is a publicly listed resource company with a 40,000-hectare portfolio of mineral claim holdings in the mineral-rich province of New Brunswick. This portfolio is built around the Goodwin Copper Nickel Cobalt project in the Bathurst Mining Camp (“BMC”) of New Brunswick. The Company drilled 10 holes in the 2025 diamond drilling campaign on the Goodwin copper-nickel-cobalt project. This followed significant copper, nickel and cobalt intercepts from 15 diamond drill holes reported by the Company in 2024. These include a 64.90 meter core interval, grading 2.19% Cu-Eq (copper-nickel-cobalt), including 3.84% Cu-Eq over a 31.20 meter core interval from hole GW24-02 as reported in a news release August 7, 2024. Significant gold values were also reported with up to 3.31 grams per tonne over 0.5m in hole GW24-01.

The Company is a project generator and expects to receive significant cash and share payments in 2026. SLAM received 1,200,000 shares plus cash from Nine Mile Metals Inc. (NINE) in 2025 pursuant to the Wedge project agreement. Also in 2025, the Company received a cash payment of $60,000 as well as 180,000 shares of a private company pursuant to the Ramsay gold agreement. The Company holds NSR royalties and expects to receive additional cash and share payments on the Wedge copper zinc project and on the Ramsay gold project.

To view SLAM’s corporate presentation, click SXL-Presentation. Additional information is available on SLAM’s website and on SEDAR+ at www.sedarplus.ca. Follow us on X @SLAMGold.Join our company newsletter by clicking SXL-News to receive timely company updates and press releases relating to SLAM Exploration.

Qualifying Statements: Mike Taylor P.Geo, President and CEO of SLAM Exploration Ltd., is a qualified person as defined by National Instrument 43-101, and has approved the contents of this news release.

CONTACT INFORMATION:
Mike Taylor, President & CEO
Contact: 506-623-8960
mike@slamexploration.com

Jimmy Gravel, Vice-President
Contact 902-273-2387
jimmy@slamexploration.com

SEDAR+: 00012459

Forward-Looking Statements
This news release contains “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking statements are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances. Forward-looking statements are often, but not always, identified by words such as “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential,” “may,” “could,” “would,” “might,” or “will,” and similar expressions.

Forward-looking statements in this news release include, but are not limited to: statements regarding the exploration potential of the Harry Brook gold-antimony project; the significance of historical gold and antimony occurrences; the interpretation of geological, geochemical, and geophysical data; the identification and prioritization of exploration targets; the anticipated receipt and significance of pending assay results from the Jake Lee Project; the continuity and extent of mineralized structures at Jake Lee and Menneval; the timing and scope of future exploration programs; the Company’s ability to advance its mineral projects; and the potential for future exploration success.

Forward-looking statements are based on reasonable assumptions made by the Company as of the date of this news release, including, without limitation: that historical exploration results, mineral occurrences, and publicly reported third-party mineral resources are relevant for regional and exploration context; that geological interpretations and targeting models are reasonable; that pending assay results will be received within anticipated timeframes; that planned exploration activities can be executed as expected; that contractors, equipment, personnel, and supplies will be available on acceptable terms; that commodity prices and market conditions will remain generally supportive; and that required permits, approvals, and access rights will be obtained in a timely manner.

Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation: the speculative nature of mineral exploration; the risk that exploration results, including pending assay results, may not confirm historical data or current interpretations; uncertainty regarding the continuity, grade, and extent of mineralization; delays or changes to exploration programs; availability and cost of labour, equipment, and contractors; fluctuations in commodity prices; availability of financing on acceptable terms; regulatory, environmental, and permitting risks; operating hazards; and general economic, market, and business conditions. Additional risk factors are described in the Company’s most recently filed Management’s Discussion and Analysis and other continuous disclosure documents available under the Company’s profile on SEDAR+.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: SLAM Exploration Ltd.

View the original press release on ACCESS Newswire

The platform that slashed NASA’s R&D costs and compressed three-day computations into one hour is now available to any organisation

Previous challenge winner’s spacecraft solution is bound for space

What do you do when your toughest technical problem stumps every expert in your building? If you’re NASA, you throw it open to 85 million minds across 140 countries. Starting today, any company can do the same.

SAN FRANCISCO, CA / ACCESS Newswire / January 23, 2026 / Freelancer (ASX:FLN) announced the global launch of its Moonshot Innovation Program, opening the breakthrough platform that has delivered over 20,000 solutions to NASA, NIH, and the CDC to enterprises worldwide.

The same system that helped NASA save 80-99% on R&D costs, compressed Bureau of Reclamation river modelling from 72 hours to 60 minutes, and generated 54 genome therapy breakthroughs for NIH is now available to any organization with a problem that traditional consulting can’t crack.

The results speak louder than any pitch deck.

NASA’s spacecraft tank venting challenge attracted 47 solutions from physicists, chemists, and aerospace engineers across multiple continents. The National Institutes of Health’s $6 million gene therapy challenge pulled in teams from Harvard, MIT, Stanford, Yale, and biotech startups, delivering 30 winning approaches in the first phase alone. The U.S. Bureau of Reclamation achieved a 60x performance improvement through an algorithm designed by someone outside traditional water management circles.

“We’ve proven something radical,” said Matt Barrie, Chief Executive of Freelancer. “The person who can solve your impossible problem might be anywhere on Earth. They might be working in a completely different industry. They might approach it from an angle your team would never consider.”

The ‘Innovation Arbitrage’

McKinsey research shows 87% of executives report critical skills gaps in emerging technologies. Meanwhile, Freelancer’s government clients have been quietly running a different playbook. They’re not hiring consultants to give them answers their own teams could produce. They’re tapping statistical diversity at scale.

“The currency for problem-solving and finding innovation is diversity,” said Steve Rader, former Program Manager at NASA’s Tournament Lab. “If you could have solved it within your domain, you would have solved it already. As soon as the speed of change is faster than your company is able to change, there is an expiration date on your company.”

The platform has processed challenges across computational fluid dynamics, genome editing, spacecraft engineering, network science, emergency response systems, and data privacy. Winners have included professors from Carthage College, retired MIT engineers, heads of chemistry at aerospace startups, and self-taught innovators who discovered unexpected talents through competition.

How It Works

Unlike traditional R&D where you pay for effort regardless of outcome, innovation challenges only pay for results. Freelancer’s team deconstructs complex problems into solvable components, designs challenges that attract the right global talent, curates responses, and manages IP transfer. Organizations choose how open to make their challenges – global, country-specific, or university-focused.

“You’re not choosing one consulting firm where everyone sits in a room and comes up with the same solution,” said Trisha Epp, Director of Innovation at Freelancer. “You’re having a competition where lots of people come up with their own divergent solutions. They each have a different, unique idea. They’re not influenced by each other.”

Recent challenges demonstrate the range. The National Institute of Standards and Technology invested $1 million in emergency response command systems integrating VR, AR, and LiDAR. NIH committed $6 million over five years to crack targeted gene therapy delivery. The Department of Commerce ran a three-year, $975K program for data privacy certification systems that reached 14 million people globally.

The Track Record

Since 2015, Freelancer has delivered:

• 20,215 breakthrough solutions

• 8,783 participating innovators

• Challenges across 140 countries

• Winners from Harvard, MIT, Yale, Tesla, IBM

• Up to 40x return on investment vs. traditional grant programs

• NASA cost savings of 80-99% vs conventional methods

The success rate led NASA to expand Freelancer’s contract from $25 million over five years (NOIS2) to $475 million over 10 years (NOIS3) – a 600% increase.

“This prize competition has been a great success to Reclamation – exceeding our set goals,” said Yong G. Lai, Ph.D., U.S. Bureau of Reclamation.

Life-Changing Successes

Winners of past challenges -when Moonshot was limited to select enterprises – have enjoyed incredible benefits. Solutions have been adopted by major aerospace contractors, spun into commercial products, advanced to spaceflight, and secured additional R&D funding.

“The most valuable outcome was validation of product strategy,” said Suzanne Borders, founder of BadVR, a woman-owned small business that won the $1 million CommanDING Tech challenge. “The hardest part of a startup isn’t the actual engineering, it’s knowing what to build and when to build it. The challenge was instrumental.” BadVR has since secured additional government R&D funding and turned their idea into a product for commercial and defense sectors.

Samer Hanoudi, an Assistant Professor at Davenport University who won NASA’s Aftershock challenge, said: “Winning this NASA challenge has significantly boosted my professional confidence and credibility, opening new opportunities for collaborations in aerospace and advanced engineering fields.”

One challenge winner’s spacecraft refueling solution is now advancing to spaceflight through partnerships with Kennedy Space Center and Johnson Space Center, demonstrating the platform’s ability to deliver not just theoretical solutions but flight-ready technology.

The Competitive Reality

This isn’t about outsourcing. It’s about what happens when the world’s brightest minds compete to solve problems that keep your executives up at night. When NASA needed lunar navigation systems, they got shadow compasses, star analog navigation tools, and modular rover designs. When they needed to detect small space debris, they got plasma signature tracking, CubeSat fleets, and a rotating tethered sweeper dubbed “SPACE BAT.”

In an era where competitive advantage is measured in months rather than years, the question isn’t whether to embrace open innovation. It’s whether you’ll do it before your competitors.

Organizations ready to solve their impossible problems can visit www.freelancer.com/innovation-challenges or contact Trisha Epp, Director of Innovation, at trisha@freelancer.com

First Challenge on New Open Platform

The first challenge for the new open version of the Moonshot Innovation Program will be “Restore Your Corner” – a $10,000 global ecosystem restoration challenge.

The challenge invites individuals and communities to document native habitat restoration efforts through video – from removing invasive species to planting native vegetation.

Prizes include regional winners and a People’s Choice Award, while creating an open-source library of restoration techniques adapted to diverse ecosystems worldwide.

The challenge – which goes live in the coming weeks – demonstrates that the platform is open to both enterprises posting technical challenges and public participation initiatives.

“Whether it’s a Fortune 500 company posting a $5 million computational challenge or a community documenting ecosystem restoration, the platform works the same way,” said Trisha Epp, Director of Innovation at Freelancer. “‘Restore Your Corner’ proves anyone can participate.”

For more information, contact:

Moonshot Inquiries:
Trisha Epp
Director of Innovation, Moonshot Innovation, Freelancer
trisha@freelancer.com

Media Inquiries:
Brent O’Halloran
Director of Communications
press@freelancer.com | +1 (650) 442 3334

About Freelancer

Thirteen-time Webby award-winning Freelancer is the world’s largest freelancing and crowdsourcing marketplace by total number of users and projects posted. More than 80 million registered users have posted over 25 million projects and contests to date in over 3,000 areas as diverse as website development, logo design, marketing, copywriting, astrophysics, aerospace engineering and manufacturing. Freelancer owns Escrow.com, the leading provider of secure online payments and online transaction management for consumers and businesses on the Internet with over US$8 billion in transactions secured. Freelancer also owns Loadshift, Australia’s largest heavy haulage freight marketplace with over 800 million kilometres of freight posted since inception. Freelancer Limited is listed on the Australian Securities Exchange under the ticker ASX:FLN and in the United States as FRLCY.

SOURCE: Freelancer

View the original press release on ACCESS Newswire

Affirming its Commitment to Sustainability

MAKKAH, SAUDI ARABIA / ACCESS Newswire / January 23, 2026 / Masar: a landmark urban development in the heart of Makkah, owned, developed, and operated by Umm Al Qura for Development & Construction Company, has been awarded LEED Gold certification under the LEED for Communities rating system, one of the highest international certifications in sustainability and the built environment. This achievement recognizes Masar’s adoption of an integrated approach that places people and the environment at the heart of its design and planning processes.

This accomplishment reflects the company’s commitment to developing sustainable urban communities in line with global best practices. By balancing quality of life, resource efficiency, and environmental protection, it paves the way for long-term positive impact and a more sustainable future.

Commenting on the achievement, Mr. Yasser Abuateek, Chief Executive Officer of Umm Al Qura for Development & Construction Company, said: “Masar Destination’s LEED Gold certification confirms our belief that cities deliver lasting value when they are designed as integrated, human-centered systems. This recognition reflects how we have approached Masar through thoughtful planning that prioritizes resource efficiency, resilience, and quality of life at the community scale. It also marks an important milestone in our work to deliver sustainable urban destinations that support the Kingdom’s Vision 2030 goals for more livable and future-ready cities.”

LEED certification is one of the most prominent global certifications for evaluating green buildings and communities. It is awarded by the U.S. Green Building Council (USGBC) to facilities that apply strict standards in areas such as energy and water efficiency, improved indoor air quality, resource management, and reduced carbon emissions, thereby enhancing environmental performance and achieving added value to the community.

The certification aligns with Saudi Arabia’s Vision 2030, supporting national objectives to create more sustainable, prosperous, and livable urban environments. As a LEED Gold-certified community at the planning and design stage, Masar Destination sets a benchmark for integrated development that balances environmental responsibility, quality of life, and long-term urban impact.

Contact Information

Khaled Karanouh
General Manager
+966 507700821
khaledk@prarabia.me

SOURCE: Umm Al Qura for Development & Construction Company

View the original press release on ACCESS Newswire

MIAMI, FL / ACCESS Newswire / January 23, 2026 / TGI SOLAR POWER GROUP (OTCMarkets:TSPG), a leader in sustainable technology and environmental real estate development, through its specialized digital marketing subsidiary ADVENT BUZZ, is proud to announce its official role as a lead sponsor and the designated Official Business Development and Marketing Partner for Earth Week Miami 2026.

Presented by The ECO Channel, Earth Week Miami (April 22-26, 2026) is the region’s premier convergence point for sustainability, innovation, and global media. As the “Global Megaphone” for the green and blue economy, this partnership allows TGI and Advent Buzz to bridge the gap between local climate action and international broadcast visibility.

Opportunities for Growth and Visibility

As the official marketing arm for this event, Advent Buzz is opening exclusive pathways for brands, entrepreneurs, and advocates to participate in this planetary mission.

Exhibitor & Media Packages

Showcase your sustainable innovations to a global audience of investors, policymakers, and media leaders.

Exclusive TGI/Advent Buzz Discount: Use promo code EARTHWEEK1 to receive a 10% discount on any exhibitor or sponsorship package.

Visibility Booster: Packages include professionally produced 10-minute televised business presentations broadcast globally on The ECO Channel.

Booking Link: Purchase Discounted Packages via Eventbrite

The ECO Ambassador Program

We are calling for environmental champions to join our mission as ECO Ambassadors or volunteers.

Impact:

Selected ambassadors will be featured across Earth Week Miami’s media channels, joining a prestigious roster that includes past honorees like Dr. Jane Goodall⁶.

Strategic Partnerships & Revenue

For organizations looking to collaborate on a deeper level, our partnership offers a 15% net commission on every exhibitor or sponsorship package sold through your network.

About Earth Week Miami 2026

Spanning across Miami-Dade and Broward Counties, the event features a curated schedule of sustainable commerce exhibitions, startup pitch competitions, beach cleanups, and VIP gala auctions. It serves as a vital platform for cities to attract global investment and engage audiences in the most pressing environmental issues of our time.

“This is about legacy,” says Michel Thomas, CEO of The ECO Channel. “Media has the power to shape culture, and through this partnership with TGI and Advent Buzz, we are giving those who care about the future a voice that can be heard around the world.”

About The ECO Channel https://www.theecochannel.com/

The ECO Channel is an online digital and streaming portal delivering news, entertainment, and education, to audiences worldwide. It is the first “green” TV Channel in the US reporting exclusively on sustainable and eco-friendly initiatives globally. The ECO Channel connects the dots by reporting on and providing high quality programming that educates, advocates and stimulates action for a healthier planet and a better, more sustainable future. https://www.theecochannel.com/

About TGI Solar Power Group Inc.

TGI Solar Power Group Inc. is a diversified holding company dedicated to acquiring innovative patented technologies and designs that enhance the quality of life while respecting the planet. Through its focus on sustainable habitats and environmental research, TGI remains at the cutting edge of green innovation.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that may cause actual results to differ materially. The Company undertakes no obligation to update any forward-looking statements.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1965: Those statements contained herein which are not historical are forward-looking statements, and as such are subject to risks and uncertainties that could cause actual operating results to materially differ from those contained in the forward-looking statements. Such statements include, but are not limited to, certain delays that are beyond the company’s control, with respect to market.

Contact:

Samuel Epstein CEO
info@tgipower.com

SOURCE: TGI Solar Power Group, Inc.

View the original press release on ACCESS Newswire

The Peace Anthem of the 21st Century

MIAMI, FLORIDA / ACCESS Newswire / January 23, 2026 / Electronic Dance Music (EDM) recording artist, Sir Ivan, has co-written and recorded a peace song that will stand the test of time. Inspired by 20th-century anti-war rock legends such as John Lennon and Bob Dylan, Sir Ivan’s new single, “Love Is The Piece,” is a bold reminder to all generations that love remains the only path to peace and is found only in our hearts.

Stream/Download On All Platforms

“As the son of an Auschwitz survivor (see UnstoppableSiggi.com), my life has been deeply affected by the tragedy of having over 50 family members murdered during the Holocaust, simply because they were Jewish. My father’s miraculous survival and my subsequent birth had a purpose. And that purpose was for me to one day write and sing a peace song that would help stop violence, bloodshed, and war between people. That song is ‘Love Is The Piece,’” declared Sir Ivan.

While global conflicts and civil unrest escalate around the world, Sir Ivan delivers a timely and powerful message with his new single, “Love Is The Piece.” Known internationally as Peaceman for his long-standing commitment to promoting peace through music, Sir Ivan brings an urgent, modern voice to the legacy of anti-war anthems.

In “Love Is The Piece,” Sir Ivan confronts one of humanity’s greatest contradictions: despite extraordinary technological and scientific achievements, we remain unable to end war. “But the one thing that they can’t seem to solve / Is the end of war – it’s time to evolve,” he sings, calling for a shift in human consciousness.

The chorus delivers the heart of the message: “Love is the piece we need for peace.” It’s a direct call to unity that resonates strongly in today’s fractured global climate.

The lyrics emphasize that pure love transcends national, religious, and cultural boundaries.
“It goes beyond Christians, Muslims, and Jews… The answer’s not blowin’ in the wind / ‘Cause our hearts hold the one solution within.”

Sir Ivan’s dedication to peace-focused artistry has been highlighted in previous press coverage, including the world premiere of his award-winning “Get Together” music video and his global DJ initiative supporting creatives in crisis.

His collaboration with acclaimed producer Markus Schulz – recently highlighted by We Rave You and EDM.com – further cemented his status as a meaningful voice in electronic music.

With “Love Is The Piece,” Sir Ivan continues his mission to inspire change through powerful lyrics. A series of forthcoming remixes from leading dance producers will help bring the message to clubs, festivals, and playlists worldwide. All streaming and download proceeds go to The Peaceman Foundation (thepeacemanfoundation.org).

About Sir Ivan
Sir Ivan is a Top 10 Billboard and Music Week recording artist, peace advocate, and philanthropist whose mission-driven catalogue blends powerful social messages with modern dance production. Often recognized for reimagining iconic anti-war and peace-driven songs, he has become one of dance music’s most distinctive voices for unity and compassion.

Sir Ivan has collaborated with Grammy Award-winning producers such as Jason Evigan, Peter Rafelson, Tracey Young, Midi Mafia, and Omar Okram, as well as other notable names, including Paul Oakenfold, Markus Schulz, and Jeff Timmons (of music group 98 Degrees), who produced the original mix of “Love Is The Piece.”

Full biography: SirIvan.com/biography

Connect with Sir Ivan:
ffm.bio/sirivan

Media Contact:
Marty True, sirivan@x-staticmusicgroup.com

SOURCE: Peaceman Productions

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / January 23, 2026 / Investors encountering SMX (NASDAQ:SMX) for the first time often start with the obvious headline: a dramatic 2025 price move. A rally exceeding 4,000% naturally draws attention, and from a trading perspective, that reaction makes sense.

But the more important question isn’t how far the stock moved. It’s why it moved-and whether the forces behind that revaluation remain intact.

Between November and late January, SMX’s market capitalization expanded from roughly $5 million to nearly $200 million. That kind of repricing doesn’t happen simply because momentum traders show up. It happens when a market begins to understand a company differently than it did before.

In SMX’s case, investors appeared to recognize something they had previously overlooked: this is not a conventional technology company. It occupies a category of its own.

What the Market Finally Understood

SMX does something few companies can claim. It embeds immutable, molecular-level identifiers directly into physical materials-metals, plastics, textiles, and even liquids-allowing those materials to carry a persistent digital identity from production through end of life.

In practical terms, SMX creates a material-level passport. Provenance, authenticity, and integrity are no longer inferred from documentation or declarations; they are verifiable attributes of the material itself, continuously available throughout the supply chain.

That capability reframed how investors viewed the company.

Some observers have compared the potential impact of this approach to earlier platform technologies that quietly reshaped daily life in the early 2000s. The comparison isn’t about consumer behavior-it’s about scale and permanence. When verification becomes embedded rather than optional, entire systems begin to operate differently.

Momentum Built on Execution, Not Narrative

The shift in perception wasn’t theoretical. It was reinforced by tangible developments.

SMX engaged with Singapore’s A*STAR on circularity initiatives, partnered with Dubai’s DMCC to monitor precious metals markets, and advanced additional programs that demonstrated real-world deployment. These weren’t aspirational announcements-they were signals of operational traction.

As those engagements accumulated, the market began to see SMX less as a concept and more as infrastructure: a company capable of redefining how sustainability, accountability, and circularity are enforced across global supply chains.

Crucially, this wasn’t driven by slogans or speculation. It was driven by proof.

The Missing Piece: A Digital Market Layer

Even with material-level verification in place, one element still needed reinforcement: a digital mechanism capable of supporting scale, monetization, and institutional participation-particularly around SMX’s Plastic Cycle Token (PCT).

That is where Kraken enters the picture.

Not as the headline. As the reinforcement.

Why Institutions Care About Structure More Than Innovation

Retail investors often focus on novelty. Institutions do not.

Large enterprises, regulators, and global partners assume innovation as a baseline. What they scrutinize instead is durability: whether a platform can withstand audits, cyber risk, regulatory oversight, and operational complexity without becoming a liability.

SMX’s alignment with Kraken addresses those questions directly.

SMX already establishes material truth. Kraken strengthens the environment in which that truth operates-enhancing execution security, permissions, and system resilience. Together, they answer the questions institutions ask before committing: Can this scale? Can it integrate cleanly? Can it operate without introducing new risk?

Those answers matter as much as any technological feature.

Why the Order of Operations Matters

It’s important to understand the sequence that brought SMX to this point.

First came molecular verification.
Then digital identity via the Plastic Cycle Token.
Only after scale and institutional relevance became real did execution-layer reinforcement arrive.

That order is not accidental.

Institutions do not adopt platforms that are still assembling their foundations. They adopt systems that appear designed for oversight from day one. SMX had already secured meaningful engagements throughout 2025. The Kraken-based treasury strategy announced recently strengthens that posture-but it does not redefine it.

The direction was already set.

Reducing Friction Where Adoption Breaks Down

One of the biggest obstacles to institutional adoption isn’t cost or capability. It’s disruption.

Kraken allows SMX to integrate into enterprise environments without forcing counterparties to rebuild their own security or treasury frameworks. That lowers barriers, shortens evaluation cycles, and accelerates confidence-particularly around PCT participation.

For institutions, that difference is decisive. Seamless integration often determines whether a platform is approved quickly or deferred indefinitely.

Confidence Compounds in Infrastructure

Once institutions adopt infrastructure, they rarely unwind it quickly. Trust compounds. Switching costs rise. Systems embed themselves.

Kraken strengthens SMX’s ability to operate under scale, scrutiny, and complexity. That isn’t flashy-but it’s exactly what institutions prioritize.

As verification requirements expand and enforcement tightens globally, platforms that function smoothly under pressure gain relevance without needing to reintroduce themselves. SMX is positioning for that moment.

Readiness, Not Noise, Drives Adoption

The recent Kraken announcement drew attention-but its real value lies in deployability, not publicity.

Kraken doesn’t make SMX louder. It makes it easier to adopt.

That distinction matters. Platforms that are operationally ready before demand becomes unavoidable are the ones institutions trust when stakes rise. SMX’s track record across materials, jurisdictions, and enforcement contexts puts it in that category.

The stock’s pullback from its highs doesn’t negate that shift. With a market cap still near $200 million-more than 4,000% above November levels-it’s clear the market remains engaged.

And with valuations once again accessible, 2026 may bring renewed attention from investors who now understand what SMX actually represents.

About SMX

SMX enables material-level verification across global supply chains, helping companies meet carbon neutrality goals and comply with evolving regulatory standards. Through its marking, tracking, measuring, and digital platform technologies, SMX supports the transition to a more transparent, accountable, and circular economy.

Contact:

Jeremy Murphy
jeremy@360bespoke.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

SAN DIEGO, CA / ACCESS Newswire / January 23, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 13,065,000 shares of common stock, issued by the Company on September 11, 2025 (the “Existing Warrants”), at reduced exercise price of $0.86 per share. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-290309). The closing of the offering is expected to occur on or about January 26, 2026, subject to satisfaction of customary closing conditions.

Roth Capital Partners is acting as the Company’s financial advisor for this transaction.

In consideration for the immediate exercise of the warrants for cash, the exercising holders will receive new Class J warrants to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”). The new Class J warrants will be exercisable into an aggregate of up to 26,130,000 shares of common stock, will be exercisable beginning on the effective date of stockholder approval of the shares issuable upon exercise of the new warrants at an exercise price of $0.86 per share, and have a term of exercise equal to five years after the stockholder approval date. The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended, or applicable under state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company has agreed to file a resale registration statement on Form S-3 with the Securities and Exchange Commission within 20 days of the closing to register the resale of the shares of common stock underlying the new Class J warrants issued in the private placement.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini as a treatment for acute kidney injury, a treatment of chronic kidney disease, prevention of post-surgical infection, and a treatment to reduce hyperinflammation and infection associated with severe burn.

For more information, please visit www.RevBiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

Company Contacts

Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: mike@plrinvest.com

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com

SOURCE: Revelation Biosciences, Inc.

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / January 23, 2026 / SMX (NASDAQ:SMX) is reshaping what the “gold standard” means in modern finance-not as a theory of currency backing, but as a system of proof. For decades, economists and policymakers debated whether gold would ever reclaim a formal monetary role. That debate cycled without resolution. What has resolved, quietly and decisively, is something more operational and more consequential: in an era defined by enforcement, sanctions, and geopolitical risk, gold’s value is increasingly determined by its ability to verify itself.

The next gold standard is evidentiary, not monetary.

Gold is entering a phase where legitimacy, traceability, and compliance are no longer secondary considerations. For regulators, custodians, and institutional holders, the defining question is no longer how much gold exists in theory, but how much of it can credibly demonstrate origin, custody, and integrity as it moves across borders, refineries, vaults, and ownership regimes. Markets that once relied on trust, precedent, and documentation are now being tested by scrutiny that those systems were never designed to withstand.

Behind the scenes, structural weaknesses have become harder to ignore. Significant portions of global gold inventories carry incomplete or inherited histories. Bars have passed through multiple jurisdictions over decades with records that are fragmented, inconsistent, or unverifiable. Legacy systems-built on refinery stamps, serial numbers, and paper trails-functioned in a slower, more cooperative world. Under today’s enforcement environment, assumption is no longer sufficient. Gold’s paradox is now visible: it is prized for certainty, yet much of it cannot independently substantiate its own past.

This is the gap SMX is designed to close.

By embedding a persistent, molecular-level identifier directly into gold itself, SMX enables the metal to carry verifiable identity through refining, transport, division, remelting, and reuse. That identity does not depend on external databases, custodial declarations, or documentation that can degrade over time. It is inseparable from the material. Gold no longer needs to be trusted-it can be tested.

For regulators, this marks a shift from inference to evidence. Compliance moves from paper-based review to material-based verification. For institutions, it introduces a clearer framework for managing counterparty, seizure, and rejection risk in a market where a single discovery of compromised inventory can reverberate broadly. And for global trade, it establishes a new distinction that markets will inevitably price: gold that can withstand inspection versus gold that cannot.

In this emerging framework, verification becomes the new gold standard. Not as a slogan or an aspiration, but as an operational requirement. Gold that can prove itself clears more efficiently, insures more readily, and trades with greater confidence. Gold that cannot increasingly carries friction, discounting, and exposure.

This transition is not speculative, and it is not distant. It is already unfolding as oversight tightens and enforcement becomes routine. As that reality settles in, liquidity will follow certainty. The gold standard is returning-but this time, it is backed not by belief, but by proof.

Contact:

Jeremy Murphy
jeremy@360bespoke.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire